查詢結果分析
相關文獻
- Comparison of Once Daily Cefpodoxime Proxetil Suspension and Thrice Daily Cefaclor Suspension in the Treatment of Acute Otitis Media in Children
- 嬰幼兒中耳炎
- 嬰幼兒高頻鼓室圖異常之臨床意義探討
- Age and the Prognosis of Tympanoplasty Type Ⅰ
- 嬰幼兒的意外傷害
- 3D Helical CT and MR Imaging of the Pediatric Airway
- 喪親者之團體心理治療--一位傷慟者領悟歷程
- Amoxicillin治療急性中耳炎之效果
- 人工電子耳植入術對病童急性中耳炎之影響
- 急性中耳炎與慢性中耳積液--過敏科醫師的觀點
頁籤選單縮合
題 名 | Comparison of Once Daily Cefpodoxime Proxetil Suspension and Thrice Daily Cefaclor Suspension in the Treatment of Acute Otitis Media in Children=每日一劑Cefpodoxime與每日三劑Cefaclor對嬰幼兒中耳炎的療效及安全性之比較 |
---|---|
作 者 | 蔡秀媛; 黃立民; 丘秀慧; 薛博仁; 李秉穎; 呂俊毅; 邱婷芳; 林曉娟; 李慶雲; | 書刊名 | 微免與感染雜誌 |
卷 期 | 31:3 1998.09[民87.09] |
頁 次 | 頁165-170 |
分類號 | 418.2324 |
關鍵詞 | 嬰幼兒; 中耳炎; 療效; Acute otitis media; Cefpodoxime proxetil; Cefaclor; |
語 文 | 英文(English) |
中文摘要 | 為了比較cefpodoxime proxetil(10 mg╱kg╱day,qd)和cefaclor ( 45 mg ╱ kg ╱ day, tid )對嬰幼兒中耳炎的療效及安全性,我們進行一項臨床隨機 試驗, 共有 57 名六個月至九歲大的嬰幼兒完成此試驗,其中 23 名以 cefpodoxime 治療 , 34 名以 cefaclor 治療。 治療後達到滿意療效的(痊癒或臨床上改善), 在使用 cefaclor 的一組佔 90 %,在使用 cefpodoxime 的一組則佔 95 %( p > 0.05 )。 門 診追蹤發現使用 cefaclor 的一組有一位再發( 3 %),使用 cefpodoxime 的一組則無再 發的病例( p > 0.05 )。 藥物安全性方面,耐受性良好的患孩在使用 cefaclor 的一組 佔 27 ╱ 32 ( 84 %),使用 cefpodoxime 的一組則佔 14 ╱ 21 ( 67 %)。 副作用 發生率在使用 cefpodoxime 的一組稍高,但統計上無顯著差異( p > 0.05 )。計算每天 的藥劑費,cefpodoxime 要比 cefaclor 來得便宜。 結論為每日一劑 cefpodoxime 對嬰幼 兒中耳炎的療效及安全性和每日三劑 cefaclor 相當,而在給藥次數及每日的藥劑費方面更 為有利。 |
英文摘要 | An open-labeled and randomized trial was conducted to compare the efficacy and safety of once daily cefpodoxime proxetil suspension (10mg/kg/day) and thrice daily cefaclor (45mg/kg/day) in the treatment of acute otitis media in children. A total of 57 children aged from 6 months to 9 years were enrolled; 23 were treated with cefpodoxime and 34 with cefaclor. Satisfactory clinical outcome, either cure or improvement, was achieved at the end of treatment in 90% of patients in the cefaclor group and 95% of patients in the cefpodoxime group (p > 0.05). Clinical recurrence was identified at the follow-up visits in one case of the cefaclor group (3%), and none in the cefpodoxime group (p > 0.05). These drugs were well tolerated by 14/21 (67%) in the cefpodoxime-treated group and 27/32 (84%) in the cefaclor-treated group. The incidence of adverse events was slightly higher in the cefpodoxime group than in the cefaclor group, however the difference did not reach statistical significance (p > 0.05). The daily cost of once-daily cefpodoxime was lower than that of thrice-daily cefaclor. We conclude that cefpodoxime administered once daily is as effective and safe as cefaclor administered thrice daily in the treatment of acute otitis media in children. The less dosing frequency and lower daily price of cefpodoxime provide additional benefits. |
本系統中英文摘要資訊取自各篇刊載內容。